{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:15:20Z","timestamp":1787501720856,"version":"build-2736575974"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Non-small cell lung cancer (NSCLC) that co-expresses thyroid transcription factor-1 (TTF-1) and p40 represents a distinct subtype of lung cancer. This case report details a 53-year-old male patient with NSCLC exhibiting co-expression of TTF-1 and p40, highlighting the need for further investigation into this unique presentation of NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 53-year-old male, nonsmoker, presented to our hospital in November 2023 with complaints of cough, expectoration, chest pain, and dyspnea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Computed tomography scans revealed perihilar lesions in the upper lobe of the right lung with distal obstructive pneumonia, invasion into adjacent mediastinal structures, multiple pulmonary metastases, possible mediastinal and right hilar lymph node metastases, pleural effusion, and a slightly thickened pleura in the right lung, along with multiple metastatic lesions in the liver. Immunohistochemical analysis showed positive staining for CK (AE1\/AE3), TTF-1, and p40, while CK56, CD68, CD45 (LCA), D2-40, and Ki-67 (50%+) were negative, leading to the diagnosis of lung adenocarcinoma. Second-generation sequencing identified mutations in ERBB2 (EXON20.p.Y772-A775dup) and TP53 (EXON5.c.404G-Tp.C135F).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient underwent 6 cycles of chemotherapy with a regimen consisting of bevacizumab, pemetrexed, and carboplatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>Posttreatment evaluations on December 28, 2023, and February 25, 2024, indicated stable disease. The patient is currently on a maintenance chemotherapy regimen of bevacizumab and pemetrexed, and his condition is stable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>The co-expression of TTF-1 and p40 in NSCLC may define a novel subtype of lung cancer. Further research is imperative to elucidate its characteristics, molecular mechanisms, and to establish its morphological features and therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000041290","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:00:08Z","timestamp":1739199608000},"page":"e41290","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["TTF-1 and p40 co-expressing non-small cell lung cancer with ERBB2 and TP53 gene mutations: A case report and review of the literature"],"prefix":"10.1097","volume":"104","author":[{"given":"Jiachun","family":"Sun","sequence":"first","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Shi","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Henan University of Science and Technology, Luoyang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wei","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxiang","family":"Su","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengkui","family":"Wang","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-0450","authenticated-orcid":false,"given":"Xinyang","family":"Li","sequence":"additional","affiliation":[{"name":"Henan Key Laboratory of Cancer Epigenetics, Cancer Institute, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1002\/cncr.35128","article-title":"Lung cancer statistics, 2023.","volume":"130","author":"Kratzer","year":"2024","journal-title":"Cancer"},{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jasc.2023.04.002","article-title":"A brief review of the who reporting system for lung cytopathology.","volume":"12","author":"Canberk","year":"2023","journal-title":"J Am Soc Cytopathol"},{"key":"R3-20250210","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/JTO.0b013e31823815d3","article-title":"\u0394np63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach.","volume":"7","author":"Pelosi","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.32074\/1591-951X-12-19","article-title":"When tumor doesn\u2019t read textbook. Third case of Ttf1 and p40 co-expression in the same tumour cells in a non-small cell carcinoma. A potential new entity to consider?","volume":"111","author":"Spinelli","year":"2019","journal-title":"Pathologica"},{"key":"R5-20250210","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/JTO.0000000000000553","article-title":"Challenging lung carcinoma with coexistent \u0394np63\/p40 and thyroid transcription factor-1 labeling within the same individual tumor cells.","volume":"10","author":"Pelosi","year":"2015","journal-title":"J Thorac Oncol"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.humpath.2018.01.023","article-title":"Non-small cell lung carcinoma with diffuse coexpression of thyroid transcription factor-1 and \u0394np63\/p40.","volume":"78","author":"Hayashi","year":"2018","journal-title":"Hum Pathol"},{"key":"R7-20250210","first-page":"100222","article-title":"Coexpression of \u0394np63\/p40 and Ttf1 within most of the same individual cells identifies life-threatening NSCLC featuring squamous and glandular biphenotypic differentiation: clinicopathologic correlations.","volume":"2","author":"Pelosi","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"R8-20250210","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.21037\/tcr-21-335","article-title":"ALK-positive pulmonary adenocarcinoma with signet ring features (PASRF) and polygonal cell morphology simultaneously co-expressing Ttf-1\/P63\/P40: a case report.","volume":"10","author":"Tan","year":"2021","journal-title":"Transl Cancer Res"},{"key":"R9-20250210","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3892\/ol.2022.13645","article-title":"p40 and TTF-1 double-expressing non-small cell lung cancer with EML4-ALK and PIK3CA gene mutations: a case report and review of the literature.","volume":"25","author":"Cai","year":"2023","journal-title":"Oncol Lett"},{"key":"R10-20250210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jtho.2022.05.009","article-title":"First report of thoracic carcinoma with DEK::AFF2 rearrangement: a case report.","volume":"17","author":"Savari","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/his.14801","article-title":"Non-small cell lung carcinomas with diffuse coexpression of TTF1 and p40: clinicopathological and genomic features of 14 rare biphenotypic tumours.","volume":"82","author":"Savari","year":"2023","journal-title":"Histopathology"},{"key":"R12-20250210","doi-asserted-by":"crossref","first-page":"13","DOI":"10.32074\/1591-951X-957","article-title":"Biphenotypic lung carcinoma with coexpression of TTF-1 and \u0394NP63\/p40 within most of the same individual cells: a further case confirming poor prognosis and a review of literature.","volume":"116","author":"Marando","year":"2024","journal-title":"Pathologica"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 keynote-189 study.","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jtho.2021.11.018","article-title":"Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (Camel-Sq): a phase 3 trial.","volume":"17","author":"Ren","year":"2022","journal-title":"J Thorac Oncol"},{"key":"R15-20250210","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 orient-11 study.","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"key":"R16-20250210","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (Gemstone-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial.","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"R17-20250210","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","article-title":"Beyond: a randomized, double-blind, placebo-controlled, multicenter, phase iii study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer.","volume":"33","author":"Zhou","year":"2015","journal-title":"J Clin Oncol"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"Impower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC.","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:00:15Z","timestamp":1739199615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041290","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}